Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Saved in:
Bibliographic Details
Title: Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.
Authors: Burston HE; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Kent OA; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Communal L; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada., Udaskin ML; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Sun RX; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Brown KR; Banting and Best Department of Medical Research, Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada., Jung E; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Francis KE; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., La Rose J; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada., Lowitz J; Antibody Solutions, Santa Clara, California, USA., Drapkin R; Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Mes-Masson AM; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.; Institut du Cancer de Montréal, Montréal, Quebec, Canada.; Département de Médecine, Université de Montréal, Montreal, Quebec, Canada., Rottapel R; Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.; Department of Medical Biophysics, Department of Immunology, University of Toronto, Toronto, Ontario, Canada.; Division of Rheumatology, St. Michael's Hospital, Toronto, Ontario, Canada.
Source: The Journal of clinical investigation [J Clin Invest] 2021 Apr 01; Vol. 131 (7).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI142677